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Background
Leiomyomatosis peritonealis disseminata (LPD) are multiple
nodules adherent to and superficially invading the peritone-
um, mimicking metastatic ovarian carcinoma. Their origin
would be metaplastic mesenchymal cells (MC), which in
susceptible women MC could originate from surgical myoma
fragments [1]. Estrogen may stimulate subcoelomic MC to
proliferate, differentiating into myoblasts, myofibroblasts, fi-
broblasts, and even decidua-like cells [2]. LPD can express
sex steroid receptors, hence be promoted by hormonal stimu-
lation, e.g., pregnancy or exogenous intake [3]. LPD is rare
(<200 cases reported), essentially benign, though malignant
transformation has been reported [4]. LPD often is asymptom-
atic but can cause abdominal distension.
Methods
We report the first case of successful management of LPD
with ulipristal, a selective progesterone receptor modulator
(SPRM), registered for preoperative management of uterine
myoma [5, 6]. All procedures followed were in accordance
with the ethical standards of the responsible committee on
human experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2000. Informed
consent was obtained from the patient for being included in
the study as the use of ulipristal in LPD is off-label.
Findings
A 21-year-old nulliparous woman presented with abdominal
discomfort coinciding with a pelvic mass stretching beyond
the umbilicus. MRI revealed multiple nodules, some with
central necrosis, all over the abdomen, apparently not origi-
nating from any abdominal organs. She had a hysteroscopic
FIGO1 myoma (3-cm diameter) resection 6 months earlier,
and 3 years before, a breast fibroadenoma had been removed.
Laparotomy disclosed multiple implants over the peritoneal
surface and bowels and their meso. Pathology of several
biopsies revealed leiomyomatosis, strongly expressing pro-
gesterone, but not estrogen receptors. She was first given
goserelin acetate 3.6 mg/month (Zoladex®) and tibolone
2.5 mg/day (Livial®) with an objective response on MRI after
3 months. This was continued for 2 years while also on a
contraceptive Cu-IUD. The therapy was discontinued because
of reassuring images, but she developed menorrhagia and a
symptomatic benign ovarian cysts (diameter=6 cm). Two
months of nomegestrol acetate 5 mg/day (Lutenyl®) rested
the menorrhagia; however, LPD seemed progressive on MRI
(Fig. 1(Acor, Atra)). After obtaining informed consent, she
started ulipristal acetate 10 mg/day for 3 months, with re-
sponse on MRI (Fig. 1(Bcor, Btra)). It was discontinued,
assuming that ulipristal would cause long-term suppression
[6]. She also developed multiple ovarian cysts up to 12.9 cm,
which were punctured because they were symptomatic. After
2 months, she became again symptomatic, coinciding with
increase in implant size, so ulipristal was restarted at the same
dosage. At this moment, while 12 months on ulipristal, she is
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asymptomatic. An endometrial biopsy revealed non-atypic
hyperplastic proliferative endometrium. A surgical debulking
is planned to allow her to stop ulipristal and to conceive.
Discussion
We believe that this first use of ulipristal for LPD was success-
ful because lesions were expressing progesterone receptors.
The subjective and objective responses were striking. Its effect
is underscored by a proven reduction in size of lesions and their
regrowth following abortion of ulipristal. Though asymptom-
atic, the disappearance of LPDwas incomplete. In addition, she
wishes to conceive, so debulking surgery was offered, though
the patient reports no side effects, which sharply contrasts with
her previous use of GnRH agonists. There is little known on
prolonged ulipristal administration. Endometrial atypical hy-
perplasia may be a concern, though never described for
ulipristal. Endometrial biopsy after 12-month exposure is how-
ever reassuring. In conclusion, ulipristal acetate may be con-
sidered as an adjunct in the management of women with LPD.
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Fig. 1 MRI view of LPD. Acor
coronal view before treatment,
Atra transverse view before
treatment, Bcor coronal view
after 3 months of treatment, Btra
transverse view after 3 months of
treatment
58 Gynecol Surg (2014) 11:57–58
